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Abstract
Background External reference pricing (ERP) is widely used to regulate pharmaceutical prices and help determine reim-
bursement. Its implementation varies substantially across countries, making it difficult to study and understand its impact 
on key policy objectives.
Objectives To assess the evidence on ERP in different settings and its impact on key health policy objectives, notably, cost-
containment, pharmaceutical price levels, drug use, equity, efficiency, availability, affordability and industrial policy; and 
second, to critically assess the quality of evidence on ERP.
Methods Primary and secondary data collection through a survey of leading experts and a systematic literature review, 
respectively, over the 2000–2017 period.
Results Forty five studies were included in the systematic review (January 2000–December 2016). Primary evidence was 
gathered via survey distribution to experts in 21 countries (January–July 2017). ERP contributes to cost-containment, but 
this is a short-term effect highly dependent on the way ERP is designed and implemented. Low prices, as a result of ERP, can 
undermine the availability of medicines and lead to launch delays or product withdrawals. Downward price convergence can 
hamper investment in innovation. ERP does not seem to promote efficiency in achieving health system goals. As evidence 
is weak, results need to be interpreted with caution.
Conclusions ERP has not regulated prices efficiently and has unintended consequences that reduce the benefits arising from 
it. If ERP is carefully designed with minimal price revisions, prudent selection of basket size and countries, and considera-
tion of transaction prices, it could be a more effective mechanism enhancing welfare, equitable access to medicines within 
countries and help promote industry innovation.
Keywords External reference pricing · Pharmaceutical pricing · Pharmaceutical policy · Regulation of pharmaceuticals · 
Systematic review · Expert consultation
JEL Classification I · I1 · I10 · I11 · I18
Introduction
External Reference Pricing (ERP) is used widely across the 
globe to inform decisions on pricing and coverage of phar-
maceuticals and is used either as the dominant method to 
explicitly set prices or as one of the criteria to inform pricing 
and reimbursement decisions [1–7]. In general, ERP oper-
ates on the basis of identifying prices from a basket of refer-
ence countries, the selection of which is based on four main 
criteria: (i) geographic proximity to the benchmark country; 
(ii) comparable GDP levels; (iii) similar socioeconomic con-
ditions; and (iv) ad hoc considerations in the benchmark 
country, such as ‘desirable’ price levels [7, 8]. In the major-
ity of cases, ex-factory prices are used to inform pricing 
decisions and pricing authorities rely mostly on list prices 
rather than transaction prices to do so [1–7]. The method 
used to calculate the reference price usually differs across 
countries; often, the lowest in the basket is used but it is not 
uncommon to use the average or the median [2, 3, 5–9]. The 
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number of countries considered in the basket as well as the 
frequency of price revisions also varies across countries. 
As a result, ERP systems vary substantially in the way they 
are implemented and, consequently, the impact of ERP is 
difficult to study compared to other pricing methodologies. 
Additionally, the way ERP is implemented in a particular 
setting is crucial due to the path-dependant nature of ERP, 
in that the features of ERP influence the size and extent of its 
impact in that setting. Hence, the prudent implementation of 
ERP can be translated in the attainment of the overarching 
policy objectives set within countries, such as availability, 
affordability and equity.
By reviewing and synthesising evidence from primary 
and secondary sources, the objective of this paper is to gain 
a clearer understanding of the impact ERP has on important 
health system goals such as cost containment, price levels, 
pharmaceutical consumption, availability and affordability, 
efficiency, equity and industrial policy, as well as to deter-
mine which factors might affect these goals positively or 
negatively. An additional objective is to provide an assess-
ment of the quality of the available evidence, its robustness 
and, by implication, its suitability to inform policy.
Our study differs from other similar studies in this area [6] 
in a number of ways. First, we combine secondary evidence 
with primary data collection such that the latter addresses 
gaps in the former. Second, we capture primary evidence 
on the impact of ERP in 21 countries in Europe, the Middle 
East, the Russian Federation, Brazil and South Africa. Third, 
in comparison to previous studies, which tend to examine a 
combination of national and international effects of ERP, 
our study provides an in-depth analysis of the performance 
of ERP against policy objectives countries have at national 
level only. Finally, as there is a lack of empirical studies 
with clear methodological design, lack of long-term evi-
dence and scarce evidence on the reasons why ERP impact 
varies across countries, we critically assess the quality of 
evidence found in the literature and study the magnitude of 
ERP effects over time. To our knowledge, no other study 
provides an up-to-date review and analysis of the impact 
of ERP on health system goals within countries, appraising 
the quality of evidence, or by drawing upon the breadth of 
country settings that we do.
Conceptual background
Decision makers resort to regulating the prices of new and 
in-patent pharmaceutical products because in-patent phar-
maceutical markets are characterised by a significant degree 
of monopoly or oligopoly. Upon entry and as a ‘first-in-
class’, a new pharmaceutical product commands monopoly 
power, while entry of similar, but slightly distinct, products 
in the same therapeutic category (also known as me-too 
products), in principle enables a degree of competition 
depending on whether therapeutic options in the same indi-
cation are considered to be perfect or imperfect substitutes. 
Still, the number of entrants in individual therapeutic indi-
cations is increasingly becoming smaller, as indications 
are becoming narrower, pointing to oligopolistic markets, 
where the options are slightly differentiated in relation to 
their therapeutic, clinical or safety features. As such, there-
fore, in-patent pharmaceutical markets are characterised by 
monopolistic competition. By leveraging intellectual prop-
erty rights and the protection they offer, innovators have an 
incentive to behave as monopolists and, as a result, enter the 
market and price at monopoly level.
Regulators, on the other hand, have an incentive to 
curb monopoly power. Different strategies can be adopted 
in this context, not all of which are mutually exclusive: 
first, they can assess the value of new products in a ther-
apeutic indication through comparative clinical benefit 
assessment or clinical and cost-effectiveness analysis or, 
even, an enhanced clinical and cost-effectiveness analy-
sis, which involves the inclusion of additional dimensions 
of value beyond incremental costs and effects; through 
that process, the price and the expected utilisation of a 
new pharmaceutical product are going to be determined. 
Second, they can adopt a costing methodology, whereby 
innovators are required to submit evidence on their cost 
structure, including R&D costs, and allowing a return 
on investment, which is fixed; this is known as a cost-
plus approach and has been used in the past to deter-
mine prices of pharmaceuticals in many settings. Third, 
they can control the return on sales (profit) or the rate of 
return on capital employed instead of controlling prices, 
which is a method that addresses profitability or return 
on capital, rather than price control. And, fourth, they 
can implement explicit price regulation and one form of 
that is comparative in nature, whereby regulators resort 
to borrowing prices from other settings, which is known 
as external reference pricing (ERP).
The popularity of ERP over the past quarter of a century 
lies in its simplicity, relative ease of adaptation and flexible 
design features, which can be used to guide and meet phar-
maceutical policy objectives. Key design features of ERP 
include, first, the selection of reference countries, which can 
be adapted to guide price diminution; second, flexibility in 
the selection of the reference price to inform price setting, 
where the focus can shift from the average or median in the 
basket, to the average in the lowest decile of reference coun-
tries, or, simply, the lowest in the basket; third, the frequency 
of re-pricing or price revisions, which enables the inclusion 
of more countries from the basket with the aim to cause 
further price reductions; fourth, the use of exchange rates as 
a means of guiding price reductions, particularly, in circum-
stances where significant currency movements are observed; 
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and, fifth, the use of differential intellectual property expiry 
dates as a means of causing further price diminution, by 
taking generic prices in patent-expired ‘reference’ markets 
and applying these in the ‘domestic’ market.
The application of ERP and its design characteristics may 
contribute to price optimisation and cost containment (or 
macroeconomic efficiency); however, it is also important 
to consider the impact this practice is having on key policy 
objectives such as utilisation (volume), access (both in terms 
of availability and affordability), efficient resource allocation 
(as opposed to macroeconomic efficiency), and industrial 
policy.
Methods
In order to study the impact of ERP at country level and how 
its implementation contributes to national policy objectives, 
evidence from both primary and secondary sources was col-
lected. Secondary evidence was collected via a systematic 
literature review (SLR), which was carried out in accord-
ance with the CRD guidelines for systematic reviews [10]. 
SLR evidence was validated, complemented and updated 
via primary data collection, carried out by surveying key 
experts across 21 countries, which were known to have 
implemented ERP either as their main method of or as a 
criterion for pharmaceutical price-setting.
Systematic literature review
Analytical framework
To inform the SLR, an analytical framework was created to 
critically assess the impact of ERP within countries. In that 
context, other frameworks for health systems and pharma-
ceutical sector policy implementation were identified and 
enhanced for this study. The WHO [11] and the OECD [12] 
have argued that the impact of pricing policies should be 
monitored beyond the management of prices [11, 12]; ulti-
mately, pricing policies must balance both static efficiency, 
namely keeping prices low relative to benefits, and dynamic 
efficiency, such as encouraging innovation through a vari-
ety of actions, including an active industrial policy [11–13]. 
However, these two types of efficiency are inter-connected as 
initiatives aiming to stimulate system-wide objectives, such 
as availability and access, require sustainable price manage-
ment [11].
WHO guidelines on country pharmaceutical pricing 
policies [11] highlight that in order to promote the use of 
affordable medicines, countries should employ pharma-
ceutical policies that address both supply- and demand-
side  imperfections. Beyond the management of prices, 
policies should align with principles of the wider health 
and pharmaceutical setting within which they operate and 
must be tailored accordingly: they should promote equitable 
access and ensure affordability and their impact should be 
monitored not only in terms of their effect on price levels but 
also on the influence they have on other outcomes, such as 
availability of essential medicines [11]. Similarly, the OECD 
assesses various pharmaceutical pricing and reimbursement 
policies that have an impact on access to effective medical 
treatments. In addition, it investigates the trade-off in phar-
maceutical policies between static and dynamic efficiency. 
By ensuring the lowest possible prices for pharmaceuticals 
today, there may be implications for both the availability of 
pharmaceuticals and the incentives for R&D, in the future 
[12].
Based on the above, we endeavoured to reflect both on 
the immediate impact of pricing policies (impact on health-
care and pharmaceutical budgets, price levels, drug use and 
consumption) and on performance measures of health sys-
tem-wide goals (availability, affordability, equity, microeco-
nomic efficiency and industrial policy). The features of this 
framework, shown in Table 1, served as our study endpoints.
Inclusion criteria (study endpoints, country selection, 
and study period)
Evidence was collected according to a set of predefined 
endpoints, based on the analytical framework presented in 
Table 1, and issues that each endpoint would address. For 
example, under ‘cost-containment’, the following issues 
were identified: (i) the ability of ERP to generate health-
care savings and (ii) the impact of the ERP design on cost 
containment. There were no country-specific restrictions 
imposed on our search to ensure that evidence from a wide 
geographical range was collected. The study period for 
inclusion of relevant published studies was from January 
2000 to December 2016. The start-date coincides with the 
period many countries started to implement ERP.
Identification of evidence (data sources and search 
strategy)
Seven electronic databases were searched for peer-reviewed 
literature (Web of Science (WoS), CINAHL, EconLit, Med-
line, ProQuest, the Cochrane Library and Scopus) using the 
following keywords: “Pharmaceutical Price Regulation” OR 
“Pharmaceutical Regulation” OR “Cost Containment” OR 
“Pharmaceutical Pricing” OR “External Reference Pric-
ing” OR “External Price Referencing” OR “International 
Price Comparisons” OR “International Reference Pricing” 
OR “International Price Referencing” AND drug OR drugs 
OR medicine OR medicines OR pharmaceutical OR phar-
maceuticals. In addition to the peer review and grey litera-
ture, a targeted search of the WHO, the WHO Collaborating 
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Centre for Pharmaceutical Pricing and Reimbursement Poli-
cies–Gesundheit Österreich GmbH (WHOCC–GOEG), the 
OECD online databases and the European Commission was 
carried out to ensure that no relevant reports were omitted. 
Relevant information was recorded and combined with the 
results of the systematic literature review.
Study selection and data extraction
The following stages were followed to select studies and 
extract data in adherence with the CRD guidelines: first, 
search results were filtered based on the relevance of the 
title and abstract to the topic. Evidence from grey literature 
was also included in the systematic review to ensure that all 
relevant studies were considered. Studies with relevant titles 
were downloaded for further examination. The main body 
of these texts was then assessed for relevance against the 
inclusion criterion: ‘mention of external reference pricing 
and its impact within countries’ at least in one of the selected 
endpoints such as price levels, affordability and access to 
provide a final set of potentially relevant studies. The num-
ber of documents presenting evidence on each endpoint was 
noted. Where one study presented evidence on more than 
one endpoint, this was recorded separately each time. An 
excel spreadsheet was used to extract the relevant informa-
tion on each endpoint from the final set of studies included 
in this study. The spreadsheet comprised titles of studies in 
rows versus the endpoints in the columns, with important 
information from the texts being extracted. Where the search 
yielded studies, which were the product of a systematic liter-
ature review, these were only included in our analysis if the 
endpoints considered were different from those set out here, 
in order to gather as much information as possible whilst at 
the same time avoiding any possible bias.
Quality of evidence
As impact assessment studies in pharmaceutical policy have 
been found to be weak, often casting doubt on many of the 
conclusions drawn [14], we critically assessed the quality of 
evidence used in this study by appraising the methodological 
design of the identified studies. Studies with strong quasi-
experimental designs (e.g. time series with a comparison 
group) and randomised controlled trials (RCTs) are con-
sidered to be well controlled compared to before–after or 
post-only studies, which are considered to be weak research 
designs, often producing unreliable impact assessments [14]. 
We categorised the studies into empirical and non-empirical. 
Table 1  ERP and its impact within countries: Summary of the analytical framework. Source: The authors
System-wide health 
policy objectives
Definition Issues raised
Cost containment Examines the extent to which ERP has the capacity to 
reduce or contain the rate of increase in pharmaceutical 
spending
ERP can lead to health care system savings
Extent of savings depends on the way ERP is implemented
Price levels Assesses whether ERP leads or is able to secure reason-
able prices for payers and healthcare systems
ERP secures low pharmaceutical prices
Pharmaceutical prices depend on ERP design
Pharmaceutical prices depend on market features
Drug use Assesses whether ERP can manage excessive drug con-
sumption
ERP impacts diffusion and use
Availability The extent to which new pharmaceuticals are available in 
the market for which they are intended
ERP can lead to market withdrawal
ERP can lead to launch delays, launch sequencing or no 
launch
Affordability The extent to which pharmaceutical prices are congruent 
with the purchasing ability of health care systems and/
or patients
ERP leads to prices in line with the purchasing ability of 
health care systems and/or patients
ERP enhances the scope for affordability
Fairness/social welfare The ability of ERP to promote equitable access to medi-
cines
ERP has an impact on social welfare
ERP has an impact on health system priorities
Microeconomic effi-
ciency
The extent to which ERP promotes health system effi-
ciency and leads to optimal resource allocation
ERP has an impact on efficient drug expenditure
ERP is associated with a stable share of pharmaceutical 
expenditure on total health spend
ERP helps contain costs while guaranteeing access to 
medicines
Industrial policy Assesses whether ERP promotes and/or is consistent with 
the objectives of industrial policy (attracting manufactur-
ing, R&D and/or related activities) or it acts as a barrier 
to attracting these
ERP impacts innovation and investment in R&D
ERP influences manufacturing and/or R&D investment 
decisions
ERP can promote innovation
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The former comprised any randomised and non-randomised 
controlled trials, studies using quasi-experimental designs 
and other quantitative analyses such as before-after and post-
only designs. The latter included theoretical models, descrip-
tive studies or other literature reviews.
To assess whether we could draw meaningful conclu-
sions from our findings, we recorded both the study design 
and timeline of all identified studies. The type of the study 
design would enable us to make inferences about the 
robustness of the evidence and the extent to which it could 
provide meaningful policy recommendations. Study time-
lines would enable us to make inferences about short- or 
long-term effects. We considered all study designs, both 
experimental (e.g. RCT) and quasi-experimental, for the 
latter applying a hierarchy that distinguishes between differ-
ent strengths (time series with comparator group; pre-post 
with a comparator group; pre-post without comparator; post 
only) [14]. In terms of the study timelines, we considered 
the likely effects of ERP on a policy variable or endpoint of 
3 years or less to be “short-term” in nature. A simple vote-
counting methodology was used to determine the accumu-
lated impact of ERP on each endpoint and issues identified 
within each endpoint. An overall scorecard was developed, 
based on three dimensions: first, the direction of impact 
(i.e. positive or negative) that ERP was found to have on the 
identified endpoints and issues; second, the quality of the 
empirical evidence considered under individual endpoints 
and issues; and third, the extent to which the studied end-
points and issues have been studied explicitly in the identi-
fied literature.
Primary data collection
Based on identified country evidence from the SLR, we 
conducted a follow-up primary data collection to validate, 
update and enhance our findings. Primary evidence was 
generated using a short survey, which was sent to key 
stakeholders in 26 countries between January and July 
2017. These countries were selected in the sample as ERP 
was used either as a primary or supportive tool in price 
setting at the time of contact. The selected stakeholders 
were leading health and pharmaceutical policy experts in 
their countries and were affiliated with national competent 
authorities (e.g. regulatory agencies, pricing departments 
or reimbursement agencies), or academic and research 
organisations. The views of pharmaceutical industry rep-
resentatives were also requested. The stakeholders were 
asked to provide evidence, and their personal perspec-
tive, on the impact of ERP within the countries they were 
responding on. The survey included six questions to pro-
vide feedback on, tailored around the endpoints and the 
associated issues shown in Table 1. The views of the expert 
responders were their own and did not represent the view 
of their institution. Stakeholders’ responses to the survey 
are referred within the text as ‘primary evidence, primary 
data or survey’ [15].
Results
Evidence generation from the systematic review 
and primary data collection
Figure 1 shows the PRISMA flow diagram of the review 
process and the respective number of articles at each stage. 
The database search yielded 6875 studies. The results of the 
systematic literature search were then combined with the 
results from the targeted grey literature search. By removing 
duplicates using the EndNote software, 3977 studies were 
initially screened based on relevant titles and abstracts. 
From the 3977 studies, 3489 were peer reviewed and 488 
were grey literature. Of the 3977 studies 3449 records were 
excluded due to irrelevance of title or abstract and 528 stud-
ies were downloaded and assessed for eligibility. Studies 
were excluded for either non-relevance to ERP or when 
internal reference pricing was studied. In addition, studies 
were excluded when only their abstracts were available and 
when studies were focusing on the international implications 
of ERP, which falls outside the scope of this review. A total 
of 45 studies were included in this systematic review.
Three studies included in this systematic literature review 
were empirical (6% of all studies considered). The majority 
of studies were descriptive in nature but also included theo-
retical models or literature reviews. When examining the 
impact of ERP against the included endpoints, a post-only 
design was used to capture the impact of ERP quantitatively.
Primary data yielded important information on the modus 
operandi of ERP and its impact on key endpoints. Twenty-
one countries (Belgium, Brazil, Bulgaria, Egypt, Estonia, 
France, Germany, Greece, Hungary, Italy, Jordan, Latvia, 
Poland, Portugal, Qatar, Romania, The Russian Federation, 
Slovakia, Slovenia, South Africa and Spain) responded to 
the survey, whereas five countries did not return a response 
(Austria, Czech Republic, Portugal, Saudi Arabia and Tur-
key). A total of 23 key stakeholders (one per country, except 
for Brazil and Hungary, that had 2 respondents each) par-
ticipated in the survey.
The role of ERP in these countries was found to range 
from “supportive” to “main method” in price setting [9]. 
Evidence on the frequency of price revisions showed that 
many countries revise their reference prices based on rea-
sons such as availability of new evidence for specific phar-
maceuticals or on specific agreements made at national 
level; a third of the countries use ERP at launch only, while 
others do not have a clear structure for price revisions and 
price recalculations may take place, for instance, every 
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6 months or at manufacturers’ request [9]. The majority of 
the countries of interest select reference countries based on 
geographical proximity, while others take into consideration 
GDP levels. The size of the basket may vary from very small 
(up to five countries) to very large (more than 25 countries) 
[9]. These features are summarised in Figs. 2 and 3. 
Results by endpoint
In the section of the results below, we endeavoured to match 
the country-specific literature findings with the evidence col-
lected from primary data. Therefore, both primary and sec-
ondary evidence is presented in alignment. A summary of 
all available evidence along with issues identified for each 
endpoint is presented in Table 2.
ERP and impact on cost‑containment
Where implemented for price-setting purposes and depend-
ing on its design, ERP is expected to have a downward effect 
on prices and contain pharmaceutical expenditure; the latter 
can be interpreted as either reducing pharmaceutical costs or 
containing their rate of growth. However, lower prices do not 
necessarily translate to overall pharmaceutical expenditure 
reductions; these also depend on other factors including drug 
utilisation. Consequently, the extent to which ERP has the 
ability to reduce pharmaceutical expenditure or contain its 
rate of increase is unclear unless key important confounders 
are explicitly accounted for. In this section we discuss the 
evidence on the impact of ERP on the overall healthcare and 
pharmaceutical spending, while the impact on price levels 
and drug use is discussed separately later in the relevant 
section.
Evidence suggests that in Europe “the conditions on 
the EU market are in effect weakening the use of cost-
based price regulation and giving more importance to the 
observed price in other European countries using external 
reference pricing” [16]. Across Europe, ERP has some-
times been shown to be effective in generating considerable 
savings for public payers in the short-term, largely depend-
ing on the ERP methodology applied, while, ERP impact 
on healthcare savings in the long-term is highly depend-
ent on the pricing policies and the economic conditions 
existing within the country and across reference countries. 
The limited ability of ERP to serve as a cost-containment 
tool in the long-term is partly attributable to the ‘fadeout’ 
effect, where ERP was successful in the short-term but 
has gradually lost its effectiveness [1]. This effect has also 
Fig. 1  PRISMA flow diagram 
outlining search results for the 
systematic literature review. 
Source: The authors
Records excluded due to irrelevance 
of title or abstract (n= 3,449)
Full text articles excluded (n=483)
Records identified through database 
searching (n= 6,875)
Additional records identified through other 
sources (n= 143)
Records after duplicates removed (n= 3,977)
Records screened (n= 3,977)
Full text articles assessed for eligibility 
against inclusion criteria (n= 528)
Final studies included (n= 45) 
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been observed with other pricing and reimbursement tools 
beyond ERP, where further adjustments were made in their 
implementation to regain their degree of effectiveness [1].
In Slovakia, the new reference system was expected to 
create savings estimated at €75 million by the end of 2012 
due to price reductions caused by ERP, but no evidence 
exists as to whether this target was actually fulfilled. This 
reformed ERP system set pharmaceutical prices based on 
the average of the two lowest in the EU, replacing the previ-
ous system, in which prices could not exceed the average 
price of the six lowest EU prices [17]. In a simple pre-post 
study without adjustment for confounders, it was found that 
in Turkey in 2007, ERP led to considerable reductions in 
pharmaceutical prices, leading to savings for the government 
of about US$ 1 billion [18]. By contrast, when ERP was 
implemented in Greece in 1996 it initially led to a reduction 
in public pharmaceutical spending but proved to be inef-
fective over the long-term as pharmaceutical expenditure 
continued to rise at rates similar to those before its introduc-
tion. This can be attributed to the replacement of older prod-
ucts by new products within the same therapeutic category 
that were more expensive and more widely prescribed by 
physicians. It has been concluded that, at least in Greece, 
emphasis on price controls only is not effective in containing 
pharmaceutical expenditure if it is not accompanied by any 
policy interventions to control proxy demand (prescribing 
and/or dispensing) and overall volume consumed [19, 20].
While savings are likely to occur for publicly funded 
health care systems, the extent of such savings depends 
largely on the way ERP is implemented. In Switzerland, 
in 2010 and 2011, changes in the implementation of the 
ERP system were made putting downward pressure on 
prices [21], by increasing the number of basket countries 
used as reference and initiating more frequent price revi-
sions [12]. Additionally, in a series of simulation exer-
cises, healthcare savings were found to be higher when 
net or discounted (rather than list) prices are used com-
pared with regular price revisions [1]: a discount or rebate 
of 20% on pharmaceutical prices in large markets with 
high GDP per capita (Germany, France, the UK, Italy, 
Spain, the Netherlands and Switzerland) would deliver 
an average pharmaceutical price decline of 47% across 
Supportive role (1) Main role (2) Other (3),(4) At launch only (5) Biannually (6) Annually (7) Every 5 years (8)
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Fig. 2  Salient features of ERP in 21 countries: role of ERP and price 
revision frequency*. Notes* The frequency of price revisions does 
not total 21 as many countries use more than one method to deter-
mine price revision frequency. For example, in Poland price revi-
sions are taking place on an  ad hoc basis  and periodically at tiered 
intervals (every 2, 3, or 5  years). (1) Countries where ERP has a 
supportive role  to price setting: Belgium, France, Germany, Hun-
gary, Italy, Latvia, Poland, Spain, Brazil, The  Russian Federation, 
Estonia. (2) Countries where ERP has a main role  in price setting: 
Bulgaria, Greece, Portugal, Romania, Slovakia, Slovenia, Egypt, Jor-
dan, Qatar, South Africa. (3) “Other” includes ad hoc, availability 
of new evidence, specific agreements, upon manufacturer’s request, 
etc. (4) Countries in the “other” frequency of price revisions: Esto-
nia, Germany, Italy, Latvia, Poland, Spain, Egypt, Jordan, Russia, 
South Africa. (5) Countries in the “at launch only” frequency of price 
revisions: Belgium, Bulgaria, Germany, Hungary, Egypt, Qatar, Bra-
zil. (6) Countries in the “biannually” frequency of price revisions: 
Greece, Bulgaria, Slovakia, Slovenia. (7) Countries in the “annu-
ally” frequency of price revisions: Estonia, Portugal, Romania. (8) 
Countries in the “every 5 years” frequency of price revisions: France. 
Source: The authors based on the literature review findings and pri-
mary data collection
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EU countries implementing ERP; this is attributable to 
the above countries being used routinely in the reference 
basket of most other European countries. Therefore, refer-
encing net or discounted prices instead of list prices will 
directly affect prices in all European countries using ERP 
by lowering basket averages [1]. In comparison, more fre-
quent price revisions (e.g. every 6 months) over a period 
of 10 years would result in a reduction of about 6% in 
pharmaceutical prices in European countries implement-
ing ERP. As frequent re-evaluations can be administra-
tively burdensome, conducting them should be balanced 
against the expected benefit [1].
ERP and impact on price levels
Extensive evidence from the literature highlighted that when 
ERP is first introduced in a country it reduces pharmaceuti-
cal prices at least in the short-term [4, 5, 8, 16, 22]. How-
ever, the long-term effects are unknown and, indeed, primary 
evidence on the ability of ERP to lead to, and secure, low 
prices on a sustainable basis, is mixed. It is important to 
highlight that evidence derived from both the literature and 
the survey does not distinguish between nominal and real 
prices.
The introduction or reform of ERP seemed to be associ-
ated with price reductions in a variety of settings, including 
the Netherlands (pharmaceutical average price level declin-
ing by 8% between 2007 and 2008) [23], Cyprus (based on a 
simulation exercise testing the effects of a likely ERP intro-
duction, after identifying Cyprus as a “high-price” coun-
try for pharmaceuticals) [24], Norway (where it has been 
regarded as very successful since 2009, resulting in con-
siderable and predictable price reductions) [25], Moldova 
(where the 2010 reform of ERP, setting ex-manufacturer 
prices equal to the average price of the three lowest prices 
in the basket, lowered prices by 3% in 2011) [26], Roma-
nia (where the prices of prescription pharmaceuticals were 
found to be low compared to the EU average due to the 
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Fig. 3  Salient features of ERP in 21 countries: Basket size and coun-
try selection criteria*. Notes *The criteria for basket selection do 
not total 21 as many countries use more than one method to select 
their basket. (1) Countries with a basket of up to 5 countries: Esto-
nia, France, Portugal, Slovenia, Qatar, The  Russian Federation, 
South Africa. (2) Countries with a basket of up to 12 countries: Bul-
garia, Latvia, Romania, Brazil. (3) Countries with a basket of up to 
24 countries: Germany, Greece, Spain, Jordan. (4) Countries with a 
basket of more than 25 countries: Belgium, Hungary, Italy, Poland, 
Slovakia, Egypt. (5) The “geographical proximity” also  included 
European countries such as Eurozone countries. (6) Countries select-
ing their basket based on geographical proximity: Belgium, Estonia, 
France, Germany, Greece, Hungary, Latvia, Poland, Slovakia, Slove-
nia, Spain, and Egypt. (7) Countries selecting their basket based on 
comparable GDP levels: Belgium, Bulgaria, Estonia, France, Ger-
many, Italy, Latvia, Portugal, Egypt, Brazil, and The Russian Federa-
tion. (8) “Other” includes countries where prices are available and 
accessible, no clear criteria, etc. (9) Countries selecting their basket 
using other criteria: Bulgaria, Latvia, Romania, Jordan, South Africa, 
Qatar, Romania. (10) Countries including in their basket the prod-
uct’s country of origin: Egypt, The Russian Federation. Source: The 
authors based on the literature review findings and primary data col-
lection
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Table 2  Summary of evidence on the impact of ERP on key policy objectives. Source: The authors based on the literature review findings and primary data collection
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
Cost-containment ERP can lead to health 
care system savings
European countries are introduc-
ing ERP to contain costs and 
increase healthcare savings. 
The evidence on the impact of 
ERP on savings varies across 
countries [1, 12, 16, 17, 19, 20]
Slovakia, Turkey, Greece, 
Switzerland
Slovakia, 2012: Eur €75 m
Turkey, 2007: 
US$900 m-US$1bn
At least in the short-term, 
ERP can be used as a tool 
to control costs, whereas in 
the long-term its impact on 
cost-savings is uncertain [1, 
19, 20]
Extent of savings depends 
on the way ERP is imple-
mented
The extent of healthcare savings 
depends largely on the way 
ERP is implemented. Frequent 
price revisions and considera-
tion of transaction prices could 
result in higher sustained sav-
ings [1, 12, 20, 21]
All EU countries and Swit-
zerland
‘Consideration of actual 
discounted prices’
‘Frequent price revisions’
Price levels ERP secures low pharma-
ceutical prices
There is a mixed evidence on the 
ability of ERP to secure low 
prices [4, 5, 15, 16, 19, 22–26, 
28–31]
The Netherlands, Cyprus, 
Norway, Romania, Bulgaria, 
Greece, Slovakia, Moldova, 
China, Belgium, Brazil, 
Germany, Egypt, Spain, 
Estonia, France, Hungary, 
Italy, Latvia, Romania, 
The Russian Federation, 
Slovenia, South Africa, 
Qatar, Jordan
The Netherlands, between 
2007 and 2008: 8% decrease 
of POM prices;
Moldova, 2012: Pharmaceuti-
cal prices decreased by 3%;
Bulgaria, 2014: Prices of 
reimbursed pharmaceuticals 
decreased between 4 and 
75.4%;
Greece, 2010: Pharmaceuti-
cal  prices decreased by an 
average of 9.5%
A limited number of studies 
consider long-term evidence 
when studying the impact 
of ERP on pharmaceutical 
prices. Therefore, whether 
ERP can or cannot continue 
to reduce prices over time 
is still unclear [1–8, 12, 25, 
38, 39]
ERP as a meaningful 
regulation to lower phar-
maceutical prices both at 
launch and over time
Evidence has shown that ERP 
reference prices (which are 
based on list prices in basket 
countries), rather than actual 
transaction prices in the 
basket countries, lead to higher 
pharmaceutical price levels in 
countries implementing ERP 
and limit the opportunities for 
these countries to benefit from 
the transaction prices attained 
in individual countries [1, 2, 
4–8, 15, 40]
All EU and OECD countries N/A
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Table 2  (continued)
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
Pharmaceutical prices 
depend on ERP design
The extent of reduction in 
pharmaceutical prices depends 
largely on the design of the 
implemented ERP. Frequent 
price revisions, larger coun-
try baskets, ’wiser’ basket 
country selection and the 
consideration of the average or 
the lowest prices in the basket 
when calculating the reference 
price, can lead to even more 
downward pressure on price 
levels [4, 6–8, 15, 21, 22, 26, 
28, 30, 32, 33]
Croatia, Austria, Belgium, 
Cyprus, Denmark, Estonia, 
Germany, Iceland, Lux-
emburg, Poland, Greece, 
Latvia, Lithuania, Slovakia, 
Switzerland, Moldova, Hun-
gary, Spain, Bulgaria, The 
Russian Federation
‘Larger basket’
‘Basket country selection’
‘Frequent price revisions’
‘Calculation of reference 
price based on average or 
lowest prices in the basket’
Pharmaceutical prices 
depend on prevail-
ing market features
Pharmaceutical price levels 
correlate with country GDP 
per capita and can be affected 
by levels of market regula-
tion, including ERP, and any 
economic pressure applied in 
the studied country [4, 5, 15, 
37–39]
Norway, The Netherlands, 
Finland, Austria, Belgium, 
Spain, Greece, Portugal, 
Lithuania, Qatar
‘Lower GDP levels’
‘Strict price regulations’
‘Other fiscal concerns’
Drug use Improved drug diffusion 
and use
There is mixed evidence on the 
impact of ERP on pharmaceuti-
cal diffusion and use. Some 
countries documented that ERP 
is not a sufficient condition for 
the diffusion and use of phar-
maceuticals, whereas others 
supported that pharmaceuticals 
diffuse well with ERP [15]
Brazil, Egypt, France, Greece, 
Hungary, Latvia, Qatar, 
Slovakia, Spain, Bulgaria, 
Estonia, The Russian Fed-
eration, Italy, Jordan
N/A There is no long-term evidence 
on whether ERP is a sufficient 
condition for improved diffu-
sion and use of pharmaceu-
ticals
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Table 2  (continued)
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
Availability and launch delays Market withdrawal ERP may result in a general 
price decrease when one 
country reduces its price, 
suggesting that if the price 
generated becomes too low, 
manufacturers may withdraw 
from the market resulting in the 
product becoming unavailable 
[2, 3, 6, 15, 28, 36]
Bulgaria, Spain, Estonia, 
Romania, Slovakia, Poland, 
Greece, Latvia
Bulgaria: 200 products were 
withdrawn from the market 
in 2012
Short-term: In Bulgaria 200 
products were withdrawn in 
2012
Long-term: Within a 6 year 
period, 11 products among 
7 EU countries were not 
launched by manufacturers in 
order to avoid expected low 
prices [6, 7, 25]
Launch delays, launch 
sequencing or no launch
Companies may delay, sequence 
or withhold drug launches in 
countries with highly controlled 
prices at ex-factory level or in 
countries where price levels are 
considered low [1, 3–8, 15, 36]
Slovakia, Hungary, Germany, 
Belgium, Poland, Estonia, 
Spain, Romania, Bulgaria, 
Greece, Latvia
Belgium: systematic delay 
of dossier submission by 
companies in order to avoid 
the Belgian price
Some companies tried to 
ignore the process or 
actively lobby for exemp-
tions for their products; 
Slovakia: after a change in 
its country basket to include 
all EU Member States;
Germany: had the highest 
availability among 15 Euro-
pean countries;
11 products among 7 EU 
countries were not launched 
by manufacturers in order to 
avoid expected low prices
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Table 2  (continued)
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
Affordability ERP leads to pharmaceuti-
cal prices in line with 
the purchasing ability 
of healthcare systems or 
patients
It has been noted that countries 
with high absolute price levels 
of pharmaceuticals, have low 
relative price levels (pharma-
ceutical prices divided by GDP 
per capita). Nevertheless, ERP 
policies (and the way ERP 
systems are designed) encour-
age higher prices in LICs, 
directly undermining afford-
ability of pharmaceuticals in 
these countries. The majority 
of countries though experience 
affordability issues at least in 
some therapeutic classes [1, 2, 
7, 15, 23, 44, 51]
Slovakia, Belgium, Brazil, 
Bulgaria, Spain, France, 
Greece, Hungary, The Rus-
sian Federation, South 
Africa, Jordan, Germany, 
Denmark, Ireland, Italy, 
Poland, Romania, Egypt, 
Qatar, Latvia, Estonia
Germany, Denmark, Ireland 
and Italy, have low rela-
tive price levels (pharma-
ceutical prices divided by 
GDP per capita);
Poland, Romania and Bul-
garia, pay relatively more 
compared to their GDP per 
capita;
In Egypt, prices are high for 
the local population in rela-
tion to per capita income
There is no conclusive and/or 
empirical evidence that ERP 
undermines affordability over 
time
Scope for increasing 
affordability
If reference prices are set based 
on some kind of affordability 
index which reflects national 
income levels, either through an 
average exchange rate or PPPs, 
affordability in LICs could be 
improved [1, 2, 44]
Egypt N/A
Fairness/Social Welfare ERP impacts social 
welfare
ERP and parallel trade had an 
effect on social welfare by 
increasing prices, therefore, 
undermining equitable and 
affordable patient access among 
EU citizens [6, 27, 40]
EU countries ‘Levelling of prices signifying 
less affordable pharmaceuti-
cal products’
There is no evidence on 
whether ERP in itself had 
an effect on social welfare; 
in combination with parallel 
trade, the use of ERP was 
associated with an effect on 
social welfareERP impacts health system 
priorities
ERP might be primarily relying 
on pricing factors extrinsic to 
the health care system in which 
it operates and subsequently 
might neglect country-specific 
health system priorities [2, 3, 
8, 46].
N/A N/A
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Table 2  (continued)
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
Microeconomic efficiency ERP has an impact on 
efficient drug spending 
(through price revision)
ERP may potentially increase 
efficiency in terms of affordable 
prices, especially through fre-
quent periodic price revisions 
of listed drugs [5]
Slovakia, Switzerland Slovakia: ERP based on the 
arithmetic mean of the six 
lowest countries within EU 
26 countries, resulted in a 
25% reduction in phar-
maceutical expenditure as 
proportion of total health 
care spending
Examples from the literature 
highlighted the short-term 
impact of ERP on efficient 
drug expenditure by lowering 
prices, although no conclu-
sive evidence was found to 
assess whether the impact 
of ERP on social equity and 
welfare is short- or long-term 
[5]
Contributes to stable share 
of drug spend as propor-
tion of total health spend
ERP might have the ability to 
reduce the share of pharmaceu-
tical expenditure in total health 
care spending [5]
Slovakia, Switzerland Slovakia: ERP based on the 
arithmetic mean of the six 
lowest countries within EU 
26 countries, resulted in a 
25% reduction in phar-
maceutical expenditure as 
proportion of total health 
care spending
Containing costs while 
guaranteeing access to 
medicines
Evidence on the impact of ERP 
on efficiency in the context 
of cost-containment, while 
maximising accessibility is 
inconclusive [6]
N/A N/A
Industrial policy ERP impacts innovation 
and investment in R&D
ERP may discourage incremental 
innovation and investment in 
R&D through: (a) downward 
price convergence potentially 
leading to reduced revenues for 
pharmaceutical companies, (b) 
encouragement of parallel trade 
potentially leading to manufac-
turers’ investing in produc-
ing only marginal product 
modifications in order to avert 
the threat of parallel trade and 
(c) the ERP objectives or rules 
themselves, and the way they 
are implemented in different 
settings and which do not nec-
essarily support industrial 
policy [3, 6, 15, 49, 51]
Slovakia, Germany, Hun-
gary, Egypt, Spain, Latvia, 
The Russian Federation, 
South Africa, Qatar, Greece, 
Romania, Italy, Estonia
Poorly defined ERP rules in 
Germany render firms less 
able to profit from incre-
mental innovation in drug 
discovery
Very limited evidence suggests 
that ERP might deter manu-
facturers from investing in 
R&D in the short-term [23]
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Table 2  (continued)
Endpoints Issues Overall evidence from primary 
and secondary sources
Countries with primary and 
secondary evidence
Quantifiable impact Short- vs. long-term effect
(1) (2) (3) (4) (5) (6)
ERP influences manu-
facturing and/or R&D 
investment decisions
There is no clear evidence on 
the impact of pharmaceutical 
policy practices on industrial 
policy decisions in Europe due 
to the multiplicity of factors 
involved and the long causality 
chain linking non-regulated 
pricing to innovation [48]
N/A N/A
ERP offers scope for pro-
moting innovation
ERP could indirectly incentivise 
innovation through favourable 
basket and other parameter 
definition. Innovation may 
be rewarded in the context of 
defining the basket of compara-
tors (i.e. inclusion of countries 
that explicitly recognize value 
and the “value of innovation”) 
or in the context of adjusting 
prices frequently to reflect price 
adjustments in other settings [8]
Slovakia, Belgium, Brazil, 
Jordan
N/A
N/A not applicable, R&D research and development, EU European Union, ERP external reference pricing, GDP gross domestic product, m million, bn billion, OECD Organisation for Economic 
Co-operation and Development, LICs Low Income Countries, PPP Purchasing Power Parity, POM prescription-only medicine
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Table 3  Overall direction and quality of evidence from the literature on the impact of ERP at national level. Source: Synthesis and assessment 
by the authors based on primary and secondary data collection
a Regarding the direction of impact of ERP, the “+” sign indicates that ERP contributes to achieving the stated goal(s); the “−” sign indicates 
that it does not contribute to achieving the stated goals. The sign “±” is used in those cases where the impact of ERP on the relevant endpoint 
and issue is ambiguous. This is generally observed when the impact of ERP depends on other factors, such as the modalities of ERP method-
ology or other exogenous factors. In order to arrive at the direction of impact as shown, a simple-vote counting methodology was adopted by 
counting the number of identified studies providing positive evidence and the number of those providing negative evidence
b Inconclusive evidence
c The overall quality of the identified empirical evidence has been classified as “high”, “moderate”, “low”, “very low” and not available. During 
vote counting only studies examining each endpoint/issue empirically were considered for quality assessment. As discussed in the Methods sec-
tion, some studies referencing evidence using a post-only design were classified as “very low” quality, whereas studies performing regression 
analysis were considered to be  of “low” quality. Where quasi-experimental designs or difference-in-difference methodologies  were used, the 
quality of evidence was classified as “high”. Under each endpoint/issue, when different types of empirical studies were considered, the quality of 
evidence was assessed based on the majority, for example, when empirical evidence under an endpoint was given by three studies using a post-
only design and one study using a regression analysis design, then the quality of empirical evidence under this endpoint was considered as “very 
low”
d The last column describes the duration of the relevant evidence and indeed whether the evidence provided under each endpoint/issue considered 
the short or long-term impact of ERP, denoted by “S” or “L”; “S/L” denotes circumstances where both short- and long-term impact are consid-
ered
Study endpoints Issues identified within endpoints on 
ERP impact
Impact of ERP positive 
(+) negative (−) or 
ambiguous (±)a
Quality of empirical evidence 
on the impact of ERP (where 
applicable)c
Duration evidence applies 
to: short-term (S) or long-
term (L)d
Cost-containment Generating healthcare savings + Very low S
Magnitude of healthcare savings 
depends on ERP design
± Very low
Prices/price levels Achieves lower pharmaceutical prices ± Very low S/L
Pharmaceutical prices depend on ERP 
design
± Very low
Pharmaceutical prices depend on market 
features
± Very low
Drug use ERP helps contain consumption ± Not Available S
ERP improves drug diffusion and use ± Not Available
Availability and launch delays Possibility of withdrawal from market + Very low S/L
ERP causes launch delays, launch 
sequencing or no launch
+ Very low
Affordability ERP leads to pharmaceutical prices in 
line with the purchasing ability of 
healthcare systems or patients
± Very low S
ERP provides scope for increasing 
affordability
± Very low
Fairness/social welfare ERP can lead to social welfare improve-
ment
-b Not Available S
ERP may neglect country-specific health 
system priorities 
− Very low
Microeconomic efficiency More affordable prices through price 
revision
+b Not Available S
Contributes to stable share of pharma-
ceutical expenditure on total health 
spend
± Not Available
Contains costs while guaranteeing 
access to medicines
±b Very low
Industrial policy and innova-
tion
May discourage incremental innovation 
and investment in (incremental) R&D
−b Very low S
May influence manufacturing and/or 
R&D investment decisions
+b Very low
May indirectly incentivise innovation ±b Very low
Overall ± Very low S
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use of ERP in 2014) [27], Bulgaria (where the government 
changed the ERP design in 2012, such that the basket was 
increased from 8 to 12 countries and yearly price checks 
were implemented for all reimbursable pharmaceuticals, 
leading to price reductions for reimbursed pharmaceuticals 
by between 4 and 75.4%) [22, 28–30] and Greece (where 
changes to the ERP system in September 2010 resulted in 
an average price decrease of 9.5% compared with the prices 
attained from the temporary price cuts regulation in May 
2010) [31]. Although the evidence derived from both the 
literature and the survey does not distinguish between nomi-
nal and real prices, in practice, all studies refer to current or 
nominal prices.
Pharmaceutical price levels within a country are influ-
enced predominantly by the nature, rules and stylised fea-
tures of the implemented ERP system. Upon implementation 
of ERP, both primary and secondary evidence suggests that 
the most influential parameters on the evolution of phar-
maceutical prices over time are the frequency of price revi-
sions, the size of the country basket, the ERP formula used 
to determine list prices and exchange rate fluctuations [4, 7, 
8, 15, 32–36]. In various simulation exercises analysing the 
reaction of pharmaceutical prices to different ERP modali-
ties, ERP systems led to reductions in pharmaceutical prices 
when (a) frequent price revisions and iterative price cuts 
were applied based on these revisions, (b) country baskets 
were very large, (c) a country used the lowest price or aver-
age of the three lowest prices in their basket rather than the 
average or median price when calculating list prices, and (d) 
exchange rate fluctuations were used proactively to achieve 
price reductions in local currency [7, 8].
Countries with no price revisions over time did tend to 
have limited price changes. In a simulation exercise test-
ing drug price evolution of 13 countries over 10 years, 
countries with the smallest price decreases were those that 
had implemented no or less frequent price revisions (Aus-
tria, Belgium, Cyprus, Denmark, Estonia, Germany, Hun-
gary, Iceland, Luxembourg, and Poland), while the highest 
decreases were observed in countries with frequent price 
revisions (Greece, Latvia, Lithuania and Slovakia) [7]. Pri-
mary evidence from Hungary confirmed that price decreases 
in the countries of its basket could not be reflected in the 
Hungarian reimbursement system because ERP would be 
used at launch only [15].
The effect of local currency depreciation on prices is also 
demonstrated in the case of the Russian Federation, where 
primary evidence indicated that the prices of internation-
ally manufactured pharmaceuticals that were first registered 
in 2009 had not undergone any price revisions until 2016, 
despite significant devaluation of the rouble. In 2016, the 
Federal Antimonopoly Service (FAS) of the Russian Fed-
eration initiated price revisions and revised prices declined 
compared to  those in 2009 [15].
Changes in the mix of basket countries have also been 
shown to influence price levels downwards. A modification 
in the Croatian ERP system in 2012 through which France 
was removed from its reference basket and replaced by the 
Czech Republic led to a reduction in most pharmaceutical 
prices [35]. Primary evidence from Spain indicated that 
price levels would depend predominately on the coun-
tries used as reference: over time, it was observed that 
prices would increase when countries with higher GDP 
per capita than Spain were included in the Spanish ref-
erence basket; in a similar vein, prices would decrease 
when countries with lower GDP per capita were used in 
the basket [15]. A similar trend was observed in Slovakia, 
where ERP initially tended to result in higher prices rela-
tive to neighbouring countries with similar income levels 
due to reference country selection, particularly because 
Germany and originator country prices were used to cal-
culate reference prices; a policy change using the mean 
of the six lowest countries in Europe was implemented in 
2009 leading to lower prices [4, 36]. The experience of 
Switzerland is in the same direction as the increase in the 
number of countries in its basket in 2010 led to a higher 
possibility of further pharmaceutical price reductions [21, 
32–34]. Lithuania expected that the inclusion of two low 
price countries (Bulgaria and Romania) in its basket in 
2012 would exert downward pressure on prices [37, 38]. 
Finally, an EU study analysing the effect of ERP on price 
levels in seven European countries for 11 pharmaceuti-
cal products between January 2003 and December 2008 
found price reductions in four of the seven countries, all 
of which calculated reference prices using the average of 
the n lowest of the basket, or the lowest available price in 
the basket [8].
Other market-specific aspects can influence the impact of 
ERP on list price levels, such as the country income level, 
the health needs of the population and healthcare costs 
[4–6, 15]. However, because confidential rebate data are not 
available, it is unclear what impact such data might have on 
actual price levels and, indeed, on reimbursed prices. An 
empirical study comparing list prices in 14 European coun-
tries and using multiple regression analysis concluded that 
prices were generally lower when a country applies ERP, 
compared with other systems of pharmaceutical pricing, 
including non-price interventions. Primary evidence from 
Qatar suggested that the introduction of ERP led to lower 
prices, following substantial price increases attributable to 
a free pricing system [15]. Further empirical work estimated 
that countries with stricter price regulation (Portugal, Bel-
gium, Greece, Spain, as well as France and Italy, at least in 
earlier years) experience lower prices than less regulated 
markets. However, the former face longer launch delays and 
access issues may ensue [39]. Finally, GDP per capita and 
price levels seem to be positively related: countries with a 
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high GDP per capita (e.g. Norway, the Netherlands, Fin-
land, Austria and Belgium) have higher price levels than 
countries with lower GDP per capita (e.g. Spain, Greece 
and Portugal) [4].
ERP may hinder generic penetration or even drive an in-
patent originator out of a market creating availability prob-
lems in specific circumstances where low generic prices 
are available in certain reference countries and are taken as 
benchmarks by ERP systems elsewhere. This can generate 
unsustainably low price levels—particularly where tender-
ing practices are implemented—as well as eliminate patent 
rights if patent expiries differ between reference countries 
and ERP implementation countries [6].
While there seems to be some demonstrable effect on 
price reductions, ERP has been criticised for not having a 
noticeable impact on price levels [8] and has been charac-
terised as a “non-optimal” pricing regulation for ensuring 
appropriate and competitive price levels compared with 
other pharmaceutical pricing systems, because (a) it impedes 
price flexibility within individual settings and (b) tends to 
reinforce narrow price corridors across settings [40]. Impor-
tantly, prices subject to ERP are increasingly disconnected 
from transaction prices. As transaction prices are not pub-
licly available, countries implementing ERP adopt increas-
ingly fictitious list prices, which tend to be systematically 
and substantially higher than transaction prices, thereby 
artificially boosting list price levels [3, 6, 8, 12]. Survey 
responses from Estonia and Latvia question whether ERP 
leads to lower or higher prices as reference prices do not 
reflect transaction prices and any additional confidential 
price discounts agreed; confidentiality restrictions, rebates, 
discounts, clawbacks and, in general, any price negotiation 
between third party payers and companies, lack transparency 
and cannot be considered under ERP [15]. Both primary 
and secondary evidence showed that the impact of ERP is 
limited in lowering pharmaceutical prices within countries 
because it is unable to account for the lower discounted 
prices when referencing other countries [2, 4, 5, 8, 15].
The availability of list (rather than net) prices suggests 
that countries using ERP may reference artificially high 
prices, while in the long-run this phenomenon renders ERP 
ineffective and irrelevant as confidential discounting and 
rebating are applied widely in pharmaceutical prices [3, 12]. 
On the other hand, official list prices offer flexibility around 
negotiations taking place between manufacturers and pricing 
authorities [40].
Overall, 11 of the 26 studies studying, among others, the 
relationship between ERP and prices used quantitative data 
to study the impact of ERP on pharmaceutical prices. The 
majority of studies presenting evidence on the impact of 
ERP on price levels were descriptive using data collected 
via post-only designs.
ERP and impact on drug use
Evidence on the impact of ERP on controlling drug con-
sumption within a country comes only from the stake-
holder survey [15]. This is hardly surprising as consump-
tion is influenced by a variety of other parameters, such as 
the number of prescribing doctors, the incentives driving 
prescribing behaviour and patient demand, among others. 
Primary data from Brazil, Egypt, France, Greece, Hungary, 
Latvia and Qatar, suggest that the uptake and the use of 
pharmaceuticals are not affected by the ERP system in place, 
indicating that product diffusion is not hindered once the 
pricing decision has been made [15]. However, primary data 
from Hungary and Greece indicated that if the budget impact 
of a product is thought to be high, the patient population 
having access to that product can be restricted in relation 
to its marketing authorisation indication [15]. Insights from 
Slovakia, Spain, Bulgaria, Estonia, the Russian Federation 
and Jordan, indicated that ERP systems were considered a 
necessary but not sufficient condition for the optimal diffu-
sion and use of pharmaceuticals [15]. When ERP was imple-
mented in Italy in the past, it was thought to be associated 
with reduced diffusion and availability of pharmaceuticals 
[33]. Lower prices resulting from the version of ERP sys-
tem implemented in Italy encouraged parallel exporters to 
shift products from the Italian market to high-price coun-
tries, thus reducing local availability and, by implication, 
adversely affecting product diffusion [15].
ERP and impact on availability and launch delays
ERP may indirectly hinder the availability of medicines [2, 
41, 42] in a number of ways, including product withdrawal 
or discontinuation, launch delays, launch sequencing and 
parallel trade. As list prices are usually set based on the aver-
age of the lowest or the lowest price in a country’s basket, 
it may result in a general price decrease when one country 
from the basket reduces its price. To avoid lower prices cas-
cading from one country to another, manufacturers have a 
number of options: for those products already on the market, 
manufacturers can withdraw from the market. For new prod-
ucts awaiting launch, ERP can lead to launch delays, launch 
sequencing, or no launch, resulting in non-availability even 
on an out-of-pocket basis, as manufacturers do not achieve 
desired price levels [2, 28].
Several literature sources have assumed that ERP might 
lead to product shortages in countries referencing the low-
est price, due to discontinuations and parallel exports [3, 
6]. This is also supported by primary evidence, particularly 
from European countries [15], where ERP is widely prac-
ticed and where the principle of regional exhaustion of intel-
lectual property rights applies, which is a necessary condi-
tion for parallel trade to take place. A study on the short- and 
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long-term effects of ERP in Europe found a discernible 
impact on availability in the countries included in the anal-
ysis, where manufacturers did not launch several products 
to avoid having to launch products at low prices [8]. Others 
have also specifically linked non-availability of medicines 
to the concept of “launch sequencing” due to ERP, whereby 
companies delay or withhold product launches in countries 
with highly controlled prices because of the knock-on effect 
lower prices will have elsewhere [1, 5–8, 36]. Overall, due 
to ERP policies, fewer drug launches and longer drug launch 
periods are likely to be the case in highly regulated and/or 
small markets compared to markets with relative flexibility 
on pricing, or markets that are large in size, with higher 
GDP, a higher percentage of GDP devoted to health and a 
higher price level of pharmaceuticals [3, 25].
Respondent insights from Slovakia, Hungary and Roma-
nia, indicated that availability issues are caused by national 
pricing regulations [15]. By contrast, both prices and availa-
bility are highest where prices are not regulated. An example 
of launch sequencing strategies due to ERP was Belgium, 
where companies systematically delayed dossier submission 
to avoid Belgian prices being included in other countries’ 
price-setting processes [7]. In recent years, however, Bel-
gium has transitioned to a system of value assessment and 
no longer relies on ERP; as such, no availability issues were 
documented since that transition [15].
In Slovakia, a change in its reference basket to include 
all EU Member States resulted in companies disregarding 
the newly implemented prices or lobbying for exemptions 
to their products, leading to access delays [5]. Similarly, 
in Bulgaria, around 200 products were withdrawn from the 
market in 2012 due to the very low prices attained by ERP 
[6, 7]. The same was mentioned in Spain few years ago, 
however, currently, due to the dual pricing system, no avail-
ability problems are documented [15]. Primary data from 
Estonia showed that there were product withdrawals when 
manufacturers were not willing to lower pharmaceutical 
prices and when reasonable therapeutic alternatives were 
present on the market, while in Romania, Slovakia and 
Poland instances of product withdrawals were also observed 
[15], suggesting that even if patients would be willing to pay 
out-of-pocket, withdrawn products would not be available. 
While some studies argue that ERP poses significant threat 
to the accessibility of medicines, particularly if any of the 
reference countries implement strict pharmaceutical expend-
iture policies due to the economic crisis [43], other studies 
explicitly recognise that their results should be interpreted 
with caution [3, 8]. Overall, if products are not reimbursed 
by a country’s health care system, in principle, they might 
be available to purchase on an out of pocket basis; it is not 
uncommon, however, that unless a (reimbursement) price 
has been agreed and which will apply to the entire market, 
the product may not available at all.
ERP and impact on affordability
Affordability is the extent to which pharmaceutical prices 
in a country align to the purchasing ability of the healthcare 
system and/or of patients. Affordability concerns have been 
raised by several survey experts in Slovakia, Belgium, Bra-
zil, Bulgaria, Spain, France, Greece, Hungary, Italy, Russia, 
South Africa and Jordan and for some therapeutic catego-
ries [15]. In Egypt, literature evidence, confirmed by expert 
opinion, showed that actual list prices of in-patent products, 
based on an extensive ERP basket of 36 countries, declined 
by a further 10% following ministerial requirements to 
improve local affordability. As some low- or middle-income 
country baskets include high income (and, potentially, high 
price) countries, this could potentially trigger issues with 
affordability, unless policy makers change pricing policies 
to adapt to the new market dynamics [44], for example, by 
considering a kind of affordability index, whereby pharma-
ceutical prices are weighed by GDP at exchange rates or pur-
chasing power parities (PPPs) [1, 2]. In Egypt reforms have 
been put on hold to allow authorities to consider a better 
alignment between Egypt and reference counties in terms of 
PPPs, although the impact of the pricing reform will remain 
unknown until the authorities review the PPP in relation to 
the potential reference countries [45]. To achieve affordable 
access to medicines, middle income countries may need to 
rely on confidential agreements with manufacturers to obtain 
lower prices through rebates or discounts and further dis-
courage any external spillover impact of their list prices [44]. 
Contrary to the evidence presented above, primary evidence 
from Qatar, Latvia and Estonia showed no detectable issues 
with affordability [15].
ERP and fairness/social welfare
Hardly any evidence was available studying welfare effects 
of ERP directly other than studies investigating price, use, 
availability or affordability issues, thereby arriving at social 
welfare impact indirectly. Much of the evidence on this end-
point comes from an evaluation of international dimensions 
of ERP and, specifically, parallel trade. Within the EU con-
text, it has been shown that ERP’s tendency to downward 
price convergence and the opportunity to conduct parallel 
trade between low- and high-price countries, (a) impacted 
social welfare by causing spillover effects from low- to high-
price countries, (b) led to barriers in patient access in low-
price markets and (c) delivered limited benefits to health 
systems and patients in terms of cost savings in high-price 
markets [6]. Therefore, ERP may undermine equitable and 
affordable patient access, particularly in low-price, low-
income countries [27]. Research also concluded that ERP 
might be primarily relying on pricing factors extrinsic to 
the health care system in which it operates [8] (by importing 
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prices from other settings) and, as a result, may not reflect 
or address country-specific health system priorities, for 
instance by calibrating prices of new products based on 
current system needs. For instance, this phenomenon was 
observed in the Russian Federation, where the national pri-
ority was to increase savings on the health care budget [46].
Several examples have highlighted that, often, countries 
pursue “beggar-thy-neighbour” practices to capitalise on the 
possibility of low prices; for example, Belgium and Aus-
tria (with a GDP per capita of US$37,883 and US$42,408, 
respectively  in 2012) referencing Romania (per capita 
GDP of US$12,802) and Bulgaria (US$14,301) or Ukraine 
(US$7,374) referencing Moldova (US$3,415), and Pakistan 
(US$2,880) referencing Bangladesh (US$2,093). Although 
there is no indication that price levels in referenced countries 
are (much) lower than in referrer countries, the latter seem 
to want to capitalise on any price differences irrespective 
of country archetype or per capita income level. In princi-
ple, such practices nurture inequalities among countries, as 
wealth differences between referrer and referenced country 
proliferate [3].
ERP and impact on macroeconomic efficiency
Evidence on the impact of ERP on the efficiency of the 
health care system and its ability to lead to effective resource 
allocation is very limited. A descriptive overview of national 
ERP systems in EU countries showed that, in terms of effi-
ciency, ERP led to a 25% reduction in the proportion of 
pharmaceutical expenditure as a percentage of total health 
care spending in Slovakia, when the country adopted the 
EURO in 2009. This was accompanied by a change in its 
ERP policy, which introduced the arithmetic mean of the 
six lowest-priced countries across EU Member States [5]. 
A Swiss study argued that reliance on external and inter-
nal price benchmarking as a basis for price setting, rather 
than pharmacoeconomic assessment, could help  ’optimise’ 
a country’s pharmaceutical expenditure [47]; in doing so, 
the potential of ERP as a mechanism to enhance efficiency 
in pharmaceutical expenditure was recognised, particularly 
through frequent periodic  list price revisions, although 
assessment of the impact of these revisions was not avail-
able. Finally, one source assessed the impact of ERP on mac-
roeconomic efficiency in the context of cost-containment 
while maximising accessibility, but the evidence was incon-
clusive [6].
ERP and impact on industrial policy
It has been argued that price convergence, generated by ERP-
based systems, discourages innovation by reducing revenues 
and acting as a disincentive for continued research and devel-
opment (R&D) investment [6], yet the evidence is not clear 
due to the multiplicity of factors involved and the long cau-
sality chain linking factors such as non-regulated pricing to 
innovation [48]. Discouraging innovation could be due to 
countries using various determinants in their ERP setup, but 
not clearly explaining whether and how these determinants are 
valued or combined, creating regulatory uncertainties, which 
might ultimately discourage manufacturers from investing in 
R&D [3]. Survey evidence from Egypt, Spain, Latvia, Russia, 
South Africa, Greece, Hungary, Romania, Italy, Estonia and 
Qatar suggested that the objectives of local ERP systems do 
not promote industrial policy [15]. Under these broad rules, 
research-based manufacturers will find themselves less able 
to profit from incremental innovation [49–51]. Despite the 
above observations, it has been suggested that even though 
encouragement of and reward for innovation are not explicit 
objectives of ERP itself as a policy tool, a positive attitude 
towards innovation may be achieved either by calibrating ref-
erence baskets to include countries that explicitly implement 
value assessment methods, or even by implementing ERP as 
a ‘light’ option, for example, at launch only [8].
Quality of evidence
Evidence on the impact of ERP on healthcare savings was 
limited and descriptive in nature. Half of the studies identi-
fied on the impact of ERP on price levels were quantitative, 
thus containing empirical evidence on impact (last column, 
Table 2), while the other half contained statements on impact 
rather than hard evidence captured in monetary terms or per-
centages. There was no evidence from the literature on the 
impact of ERP on drug consumption. The evidence on the 
quantifiable impact of ERP on market withdrawal and/or 
launch delays of pharmaceutical products was of very low 
quality (Table 3). Although some empirical evidence was 
identified regarding the impact of ERP on affordability of 
medicines within a country, little was identified in terms 
of quantifying the extent to which affordability of medicines 
would be affected as a result of ERP policies. A very limited 
body of evidence, largely descriptive in nature, was identified 
on the impact of ERP on equity, while literature relevant to 
the impact of ERP on macroeconomic efficiency was scarce 
and inconclusive. Finally, the available empirical evidence on 
the effects of ERP on industrial policy was both scarce and of 
very low quality. Table 3 presents the overall direction (posi-
tive vs. negative vs. inconclusive) and quality of evidence 
found in the literature on the impact of ERP at country level.
Discussion and policy implications
As evidence found in the literature on the impact of ERP 
on a number of health system objectives was weak and of 
low quality in the majority of cases, primary data were 
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collected to validate, complement, update and enhance our 
understanding of the impact of ERP at country level. Over-
all, ERP seems to contribute to cost containment by exert-
ing downward pressure on pharmaceutical prices, at least 
in the short-term following its introduction. However, the 
magnitude of healthcare savings depends largely on ERP 
design. Increases in the number of basket countries as well 
as more frequent price revisions are likely to lead to greater 
reductions in pharmaceutical prices and will in principle 
generate healthcare savings. Nevertheless, these savings can 
be limited because transaction prices remain elusive and list 
prices, which are used in reference price setting, are increas-
ingly fictitious.
Results on the impact of ERP on price levels varied 
between secondary and primary evidence. Based on the 
literature, upon its introduction, ERP has the ability to 
reduce pharmaceutical prices, whereas mixed evidence was 
documented from primary sources on this endpoint. This 
is because price levels within countries are influenced by 
the nature and the rules of the ERP system. Again, frequent 
price revisions, the basket size and the formula used to cal-
culate reference prices can determine the extent of price 
reductions observed within countries. A study in the same 
series discusses how ERP is implemented and the varia-
tions observed in the ERP design across countries [9]. Other 
aspects of the market can have an impact on price levels, 
such as country income level, the health needs of the popu-
lation and overall healthcare costs. Despite the documented 
price declines, ERP has been criticised both in the literature 
and by experts as being a “non-optimal” pricing regulation 
not resulting in appropriate and competitive price levels 
over time compared with other approaches to pharmaceuti-
cal pricing, such as cost-effectiveness or value-based pricing 
(VBP). When a country refers to source settings where VBP 
is applied, additional concerns may arise about the ability 
of ERP to secure low prices where it is applied: as reim-
bursement is often available for selected (usually high-risk) 
populations, prices in source countries can be higher than 
might otherwise be the case [52].
Over time and in a number of settings, the role of ERP 
in price setting has transitioned from primary to supple-
mentary. To that end, ERP is either the starting point for 
price negotiations or is used in combination with other 
tools to determine prices; this highlights the limits of 
ERP’s effectiveness as a pricing tool, since it is based on 
list rather than net prices. Consequently, ERP-derived 
prices are not considered final, but, rather, an upper ceil-
ing for the purposes of negotiation [9].
The weak link between ERP and drug use was high-
lighted in the survey where the importance of arrangements 
and incentives on the proxy demand- (through approaches 
to prescribing, dispensing, clinical guidance and financial 
and non-financial incentives) and the demand-side (cost-
sharing), were underlined.
Downward price convergence and the prospect of 
reduced manufacturer  revenues can be detrimental for 
medicines availability and incentivize manufacturers to 
adopt launch sequencing strategies, in an attempt to avoid 
a downward price spiral by delaying the launch of new 
products in low-price countries or in countries with highly 
regulated prices at ex-factory level. Again, the modality 
of ERP implementation is important and seems to partly 
determine the extent of launch sequencing and, through 
that, availability. For example, ERP at launch only does 
not seem to have an impact on availability, whereas ERP 
associated with frequent price revisions and combined 
with unrealistic exchange rates or intense exchange rate 
fluctuations, does.
Availability problems may also be triggered by different 
patent expiries between jurisdictions. Circumstances have 
been reported where patent expiry and subsequent generic 
entry at a significantly reduced price in one setting has trig-
gered price revisions in another where the drug in question 
is still on-patent; if the price diminution in the latter is based 
on the generic price borrowed from the former, there is a 
risk of withdrawal from the market if an on-patent origina-
tor is assigned the price of the generic. In this case, while 
the objective of decision makers is to improve affordability, 
the end result may be reduced availability, as the on-patent 
product may be withdrawn from the market if exposed to 
imported generic price competition. The broader implica-
tion is that, if this occurs on a frequent basis and across 
settings, it will unavoidably carry negative implications for 
long-term commitments to R&D investment apart from the 
issues related to availability.
As far as affordability is concerned, several countries 
rely mostly on confidential agreements to obtain lower net 
prices through rebates and discounts. ERP does not seem 
to promote efficient resource allocation and may shift the 
welfare equilibrium within a country due to higher, unaf-
fordable prices relative to the GDP per capita of the country. 
Undoubtedly, there is a bi-directional relationship between 
the impact of ERP within a country and across countries. 
Launch delays in third countries could result in non-avail-
ability of pharmaceuticals in some small and low-income 
countries. Launch-sequencing strategies adopted by manu-
facturers can lead to reduced availability of medicines in 
smaller markets or in countries with lower prices. Therefore, 
when studying the impact ERP has on a country, the impact 
ERP has beyond a country’s borders needs to be acknowl-
edged [53].
Despite the relative abundance of studies found on the 
impact of ERP on cost containment, prices, availability 
and launch delays compared to other endpoints, evidence 
on the quantifiable impact of ERP on these endpoints is 
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of low quality and largely inconclusive to support claims 
about sustainable savings, price diminution or poor avail-
ability due to ERP. For example, the validity of evidence 
provided on the quantifiable impact of ERP on healthcare 
savings is limited and subject to criticism as the majority 
of studies were descriptive, using a post-only design; only 
three studies assessed the ability of ERP to generate health-
care savings over time [1, 19, 20]. Overall, therefore, the 
strength of evidence regarding cost containment was found 
to be weak and the quality of evidence low. Some evidence 
was found in relation to the impact of ERP on affordability 
of medicines within a country, but little of substance was 
identified that would quantify the extent to which afford-
ability of medicines would be affected as a result of ERP 
policies. A very limited body of evidence, largely descriptive 
in nature, suggests that ERP does not necessarily reflect the 
goals and priorities of the health system in which it operates, 
that it may shift the welfare equilibrium within a country due 
to higher pricing and that subsequent affordability issues 
arise as a direct consequence of ERP. Equally, literature on 
the impact of ERP on macroeconomic efficiency is limited 
and inconclusive. Consequently, the quality of evidence on 
the impact of ERP within a country is weak, it emerged 
from a limited number of empirical studies, the majority 
of which were based on qualitative analyses of survey data 
or regression analyses of observational data, which could 
not be controlled for bias and/or potential confounders. No 
relevant studies were found that assessed or quantified the 
impact of ERP by employing methods that allow for causal 
inference, such as time series or panel data analyses. Based 
on this, it is difficult to draw distinctly positive or negative 
conclusions about the effects of ERP. As such, some of the 
results of this review should be interpreted with caution and 
care should be exercised when inferences are made about the 
long-term implications of ERP.
Our analysis is not without limitations. The first limita-
tion relates to our results being limited to the English lan-
guage only and there may be studies in other languages, 
which we could not account for. However, the expert input 
into this study will have mitigated the extent of gaps in our 
analysis. A second limitation relates to a substantial propor-
tion of studies reviewed being quite dated; this is impor-
tant as countries may have moved to alternative methods 
of pricing. Similarly, expert insights have been useful and 
provided updated evidence. Third, the effect of ERP as an 
isolated policy is very difficult to disentangle in the presence 
of other regulatory interventions implemented both within 
the country that implements it, but also in reference coun-
tries. Therefore, in the presence of several confounders, it 
is not possible to draw robust conclusions on the impact 
of ERP. Fourth, data on discounts and rebates remain con-
fidential, therefore our study of the impact of ERP is lim-
ited to list prices rather than transaction prices. Given the 
confidentiality surrounding transaction prices, it is doubtful 
that this can be addressed in any particular way. Finally, as 
pharmaceutical pricing policies are constantly undergoing 
updates and reforms, the evidence presented in this study 
may not reflect the policy landscape in future years. How-
ever, this study provides a benchmark at this point in time 
for future analyses.
Conclusions
Based on a combination of primary and secondary evidence 
on the impact of ERP within countries, the following conclu-
sions can be supported at national level: first, when ERP is 
implemented, pharmaceutical expenditure can be contained 
or even decline at least in the short-term because prices may 
decline; however, this effect may altogether be annulled if 
there is no effective control on volume. Second, the avail-
ability of and equitable access to pharmaceuticals, as well as 
the promotion of industrial policy can be undermined when 
ERP is used to inform pricing at national level. Third, the 
impact of ERP on the affordability of medicines is ambigu-
ous and subject to the design features of the policy. Fourth, 
the impact of ERP on policy objectives such as sustaina-
ble price levels, cost containment and availability, depends 
predominantly on the way ERP is implemented in a specific 
setting as well as on extrinsic factors, such as launch delays 
in other countries. Finally, this is the first review that criti-
cally assesses the quality of the evidence found in the lit-
erature on the impact of ERP on health and pharmaceutical 
policy objectives. We have identified studies, the majority 
of which rely on weak non-experimental study designs and 
conduct post-only analysis. To some extent, therefore, the 
results identified above need to be interpreted with caution 
as it is not possible to make inferences about the impact of 
ERP on individual policy variables and its overall impact 
within countries. Longer-term studies and better designs 
are needed in this context to draw more robust conclu-
sions. Overall, it has been shown that ERP constitutes one 
approach to pricing; however, it is implemented with a vari-
ety of different modalities depending on the salient features 
used each time. Whereas some of the ERP implementation 
modalities may be associated with negative implications 
regarding access, availability or delays in product launches, 
other modalities are more neutral to these critical variables. 
Despite its obvious limitations, ERP should not be altogether 
dismissed as improvements can clearly be made in the way 
it is implemented.
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